CTI BioPharma
Seattle · Founded 1991
About CTI BioPharma
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
Company Facts
- Founded: 1991
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $254.8M
- Funding stage: M&A
- Last round: Post-IPO Debt (Aug 2021)
- Ticker: nasdaq:CTIC
- Website: ctibiopharma.com
- Phone: +1 206-282-7100
Industries & Categories
Biopharma, Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cti-biopharma-183728 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.